Thursday, 8 October 2015

Time spent on Dabrafenib+Trametinib 

Interesting spider graph at ECC2015 on Dabrafenib and Trametinib a known combination of a Braf inhibitor and a Mek inhibitor. A subset of patients can make it longer than others -meaning that their tumour resistance to the treatment is occurring much later (>2 years). As seen patients with a slow reduction of tumours tend to stay longer on treatment than the ones experiencing a rapid shrinkage.

No comments:

Post a Comment